Cryopreservation, 361 versus 351 Outcomes: How Frozen Starting Material Changes the Clinical and Manufacturing Picture

Written By Samuel Molina, PhD

Cryopreservation became routine for hematopoietic and cellular therapies during the COVID‑19 era. That operational shift revealed a simple truth: the same freeze–thaw effects on collected starting material (CSM) have different clinical and programmatic consequences depending on whether the material is used directly as a 361 HCT/P or as a 351 biologic manufacturing input. This post compares outcomes and operational implications for 361 patients (direct clinical transplants) versus 351 patients (those whose cells enter GMP manufacturing), and embeds verbatim, citable quotes and DOI‑linked references.

What cryopreservation does to the graft

Laboratory and clinical studies show that cryopreservation can preserve numeric viability while reducing functional activity and altering accessory‑cell composition. Peer‑reviewed analyses link these changes to measurable clinical signals. As Harrison and colleagues put it:

“Variability in leukapheresis collections remains a major source of manufacturing failure in autologous cell therapies.” (Harrison et al., 2021). DOI: https://doi.org/10.1016/j.drudis.2021.08.010

Clinical series from the pandemic period report that cryopreserved grafts often preserved median neutrophil engraftment but showed subgroup signals for platelet recovery. One study summarized the clinical pattern succinctly:

“During the COVID‑19 pandemic, cryopreserved HSCs did not have a negative impact on median engraftment time and OS when compared to fresh HSCs. In the MUD group, platelet engraftment rate was lower in cryopreserved HSC recipients.” (Strzelec et al., 2024).
DOI: https://doi.org/10.21873/invivo.13565

Mechanistically, reviews and white papers emphasize that cryo‑induced reductions in functional CD34+ recovery and loss or dysfunction of accessory/support cells plausibly underlie these clinical signals (Harrison et al., 2021; Informa Connect, 2022).

361 HCT/P clinical outcomes: what clinicians observe

When CSM is used directly for transplantation under 361 HCT/P practice (autologous or minimally manipulated allogeneic grafts), the typical clinical pattern is:

  • Neutrophil engraftment: Frequently similar between fresh and cryopreserved grafts in many cohorts; median days to neutrophil recovery often show no significant difference (Strzelec et al., 2024).

  • Platelet engraftment: More sensitive to cryopreservation in some donor types (notably matched unrelated donors), with lower platelet‑engraftment rates reported in specific series.

  • Supportive care impact: Cryopreserved graft recipients may require more platelet transfusions or longer monitoring, but many centers manage these needs within standard transplant pathways.

  • Clinical acceptance: Because 361 use is a direct clinical intervention, teams often accept some variability and mitigate risk with supportive measures rather than rejecting the graft outright.

These clinical observations align with the mechanistic concern that cryopreservation can reduce functional stem‑cell and accessory‑cell activity even when numeric CD34+ counts appear adequate (Harrison et al., 2021).

351 biologic outcomes: why the same changes matter more for manufacturing

For cells destined to become a 351 biologic (GMP manufacturing for CAR‑T, gene‑modified products), the consequences of cryo‑induced changes are different in kind:

  • Manufacturing comparability and release: Sponsors must demonstrate that frozen starting material is comparable to fresh material. The FDA emphasizes the centrality of starting‑material quality:

    “The quality of the starting material is critical to the success of manufacturing autologous CAR T cell products.” (FDA, 2020). PDF: https://www.fda.gov/media/136703/download

  • Manufacturing failure risk: Reduced functional CD34+ or impaired T‑cell fitness can lead to failed expansion, out‑of‑spec potency, or inability to release a product — outcomes that prevent infusion entirely rather than merely delaying recovery.

  • Operational consequence: A failed manufacturing run often means the patient loses the intended therapy or requires a new collection and re‑consent, with major clinical and logistical consequences. Harrison et al. link collection variability directly to manufacturing failure risk.
    DOI: https://doi.org/10.1016/j.drudis.2021.08.010

In short, the same cryo‑effects that produce manageable clinical delays in 361 practice can translate into non‑deliverable therapy in a 351 manufacturing pathway.

Why regulatory and operational context changes the outcome

Regulatory frameworks and site capabilities shape how cryo‑effects translate into patient outcomes:

  • 361 HCT/Ps are governed by HCT/P rules that allow clinical teams to use minimally manipulated material with clinical oversight (21 CFR 1271). Clinical tolerance for variability and supportive care pathways can absorb some cryo‑related deficits.

  • 351 biologics must meet full GMP, validated comparability, and potency/release criteria (21 CFR parts 210/211; biologics parts). Sponsors and manufacturers, therefore, have a lower tolerance for functional loss in starting material; the FDA’s guidance makes starting material quality a gating factor for manufacturing success (FDA, 2020).

Industry analyses underscore supply‑chain fragility for autologous products: “Autologous cell therapy supply chains are uniquely vulnerable due to their reliance on patient‑specific starting material and just‑in‑time scheduling” (Informa Connect, 2022). That fragility magnifies the operational impact of cryopreservation in 351 pathways.

Practical recommendations (evidence‑based)

  1. Measure functional potency post‑thaw (CFU, T‑cell potency) rather than relying solely on numeric CD34 counts; reduced functional recovery predicts downstream risk (Harrison et al., 2021).

  2. For 361 programs, plan for enhanced platelet support and monitoring when using cryopreserved unrelated‑donor grafts (Strzelec et al., 2024).

  3. For 351 programs, require validated comparability data for frozen starting material and consider higher collection targets or fresh‑use pathways where feasible to reduce manufacturing failure risk (FDA, 2020).

  4. Document and harmonize collection, cryopreservation, and thaw protocols across sites to reduce variability that drives both clinical and manufacturing risk (NMDP; Informa Connect).

References

Samuel Molina, PhD
Next

Kymriah (tisagenlecleucel) - The Lone Wolf of Cryopreserved CSM